Subscribe
Sign in
Home
Notes
Let's get ready for ESMO 2025!
Post-ESMO 2025!
Archive
About
Latest
Top
Discussions
Are fears of rising cancer in young adults exaggerated? A live talk with Ade Adamson
A recent JAMA Internal Medicine study sheds light on this question!
Nov 3
•
Timothée Olivier
17
3
2
38:57
October 2025
The Iceberg Plot: A Visual I Conceived to Differentiate Tumor Biology from Treatment Effect.
I would like to emphasize a plot we published together with Vinay Prasad and Mark Lythgoe.
Oct 29
•
Timothée Olivier
13
2
1
Post-ESMO 2025 on Adjuvant CDK4/6 Inhibitors after MonarchE and NATALEE Updates.
With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high.
Oct 26
•
Timothée Olivier
23
10
4
Reduce Toxicity and Save Money: The Paper and Website to Bookmark for Alternative Dosing in Oncology!
The website to boomark: https://oncdoc.org/
Oct 24
•
Timothée Olivier
19
3
3
Solving Racial Inequalities in HLA-Restricted Therapies: Lessons from ESMO 2025.
Access to HLA-restricted therapy differs according to patients ethnicity, and should ideally be overcome.
Oct 21
•
Timothée Olivier
9
2
1
Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials
This is the title of our recent JAMA Internal Medicine publication.
Oct 14
•
Timothée Olivier
9
1
1
Multiplicity in oncology randomized trials: an approach to the KEYNOTE-B96 trial with a detour via bevacizumab
PD(L1) blockade in patients with ovarian cancer…
Oct 9
•
Timothée Olivier
13
Adjuvant CDK4/6 Inhibitors Still Under Debate: Preparing for the NATALEE and monarchE Updates at ESMO 2025.
With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high.
Oct 5
•
Timothée Olivier
15
The POTOMAC Trial
In february 2019, the POTOMAC trial was announced, focusing on high-risk non-muscle invasive bladder cancer (NMIBC).
Oct 4
•
Dries Develtere
16
3
1
September 2025
Will PSMAddition Deliver?
I’m thrilled to share a guest post by Dries Develtere as part of our “Let’s Get Ready for ESMO 2025!” series.
Sep 28
•
Dries Develtere
11
Let's get ready for ESMO 2025 with the KEYNOTE-905 trial! Does EV-Pembro in perioperative bladder cancer set a new standard of care?
We should wait to see the data at ESMO before making any decisions.
Sep 25
•
Timothée Olivier
9
Is optimal treatment duration in cancer mostly arbitrary?
A hint: most cancer treatment durations are multiples of years.
Sep 22
•
Timothée Olivier
18
3
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
